Category: Featured

14 Dec

December 2022 Update

Daniel Tillett ASX Release, Featured, Media Release, Video

Race is pleased to announce the appointment of global pharmaceutical and commercial leader, Mr Damian Clarke-Bruce, as Managing Director and Chief Executive Officer, effective 1 February 2023. Mr Phil Lynch will return to his prior role as a Non-Executive Director…

Read More
09 Dec

Race Submits Human Ethics Application to Commence Cardioprotection Breast Cancer Trial

Daniel Tillett ASX Release, Featured, Media Release , , ,

Read More
05 Dec

Danny Sharp appointed an Independent Non-Executive Director of Race

Daniel Tillett Featured

Read More
29 Nov

Race Oncology 2022 AGM Presentation

Daniel Tillett Featured, Media Release, Video , , ,

Race Oncology 2022 AGM Presentation by CEO Phil Lynch and CSO Dr Daniel Tillett.

Read More
23 Nov

Race Receives Positive Guidance on Zantrene via Pre-IND Meeting with US FDA

Daniel Tillett Featured , , ,

Read More
17 Nov

Race Oncology EMD AML Trial Featured on NBN News

Daniel Tillett Featured, Media Release, Video , ,

Read More
02 Nov

Race Oncology Investor Briefing – Melbourne 20th Oct 2022

Daniel Tillett Featured, Media Release, Video , , , ,

Read More
27 Oct

September 2022 Quarterly Activity Report & Appendix 4C

Daniel Tillett Featured

Read More
26 Oct

Pitt St Research interview with Race Oncology’s CEO Phil Lynch & CSO Dr Daniel Tillett

Daniel Tillett Featured, Media Release, Video , ,

Read More
17 Oct

Pitt Street Research Initiates Coverage of Race Oncology

Daniel Tillett Featured, Media Release, OPINION EDITORIAL , , , , ,

Race Oncology Limited (ASX:RAC) is an Australian pharmaceutical company focused on the development of its key drug, Zantrene, which is currently being studied for pre-clinical and clinical efficacy in several cancer indications. Zantrene is a highly targeted precision oncology agent…

Read More